| Autor: |
Anika Wranke, Benjamin Heidrich, Stefanie Ernst, Beatriz Calle Serrano, Florin Alexandru Caruntu, Manuela Gabriela Curescu, Kendal Yalcin, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V Papatheodoridis, Birgit Bremer, Judith Stift, Jan Grabowski, Janina Kirschner, Kerstin Port, Markus Cornberg, Christine S Falk, Hans-Peter Dienes, Svenja Hardtke, Michael P Manns, Cihan Yurdaydin, Heiner Wedemeyer, HIDIT-2 Study Group |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 9, Iss 7, p e101002 (2014) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0101002 |
| Popis: |
Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6-12).Anti-HDV IgM serum levels were negative in 18 (15%), low (OD |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
